［1］K Ramsden,J Laskin,C Ho,et al.Adjuvant chemotherapy in resected stage II non-small cell lung cancer:Evaluating the impact of dose intensity and time to treatment ［J］.Clin Oncol,2015,27(7):394-400.
［2］Zhang Tongtong,Li Qing.Neurokinin 1 receptor blocking agent-a new choice to alleviate nausea and vomiting caused by chemotherapy［J］.Oncol Progress,2013,11(4):351-355.［张童童，李青.神经激肽1受体阻断剂-缓解化疗所致恶心呕吐的新选择［J］.癌症进展，2013，11（4）:351-355.］
［3］Wang Ying,Lin Yincheng.Progression in the treatment of delayed chemotherapy-induced nausea and vomiting［J］.Chin Clin Oncol,2014,19(10):945-949.［王盈，林英城.延迟性化疗相关性恶心呕吐的治疗进展［J］.临床肿瘤学杂志，2014,19（10）:945-949.］
［4］Bergstrom M,Hargreaves RJ,Burns HD,et al.Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant ［J］.Biol Psychiatry,2004,55(10):1007-1012.
［5］Hesketh PJ,Grunberg SM,Gralla RJ,et al.The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting：a multinational，randomized，double-blind，placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 study Group［J］.J Clin Oncol,2003,21(22):4112-4119.
［6］Poli-Bigelli S,Rodrigues-Pereira J,Carides AD,et al.Addition of the neurokinin-1 antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting.Results from a randomized,double blind,placebo-controlled trial in Latin America［J］.Cancer,2003,97(12):3090-3098.
［7］Zhang Li.Application of aprepitant in China CINV patients［J］.Oncol Progress,2011,9(6):610-612.［张力.阿瑞匹坦在中国CINV患者中的应用研究［J］.癌症进展,2011,9(6):610-612.］
［8］Jorn Herrstedt,Fausto Roila.Updated MASCC/ESMO consenus recommendations:Prevention of nausea and vomiting following high emetic risk chemotherapy［J］.Support Care Cancer,2017,25(1):295-296.
［9］Hesketh PJ,Bohlke K,Lyman GH,et al.Antiemetics:ASCO clinical practice guideline update［J］.J Clin Oncol,2016,34(4):381-386.
［10］Antiemesis:NCCN clinical practice guidelines in oncology［M］.National Comprehensive Cancer Network,2016,1:MS8-9.
［11］Aapro M,Carides A,Rapoport BL,et al.Aprepitant and fosaprepitant:a 10-year review of efficacy and safety ［J］.Oncologist,2015,20(4):450-458.
［12］Grunberg S,Chua D,Maru A,et al.Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associate with cisplatin therapy：randomized,double-blind study protocol-EASE［J］.J Clin Oncol,2011,29(11):1495-1501.
［13］Saito H,Yoshizawa H,Yoshimori K,et al.Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin:a multicentre,randomised,double-blind,placebo-controlled phase 3 trial［J］.Ann Oncol,2013,24(4):1067-1073.
［14］Ando Y,Hayashi T,Ito K,et al.Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy［J］.Support Care Cancer,2016,24(2):871-878.
［15］Rapoport B，Chua D,Poma A,et al.Study of rolapitant,a novel,long-acting,NK-1 receptor antagonist,for the prevention of chemotherapy-induced nausea and vomiting(CINV)due to highly emetogenic chemotherapy(HEC) ［J］.Support Care Cancer,2015,23(11):3281-3288.
［16］Bernardo L Rapoport,Martin R Chasen.Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer:two randomised,active-controlled,double-blind,phase 3 trials［J］.Published Online,2015,16(9):1079-1089.
［17］Natale JJ,Spinelli T,Calcagnile S,et al.Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron：review of clinical data［J］.J Oncol Pharm Pract,2016,22(3):485-495.
［18］Hesketh PJ,Rossi G,Rizzi G,et al.Efficacy and safety of NEPA,an oral combination of netupitant and palonosetron，for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy：a randomized dose-ranging pivotal study［J］.Ann Oncol,2014,25(7):1340-1346.
［19］Aapro M,Rugo H,Rossi G,et al.A randomized phase III study evaluating the efficacy and safety of NEPA,a fixed dose combination of netupitant and palonosetron,for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy［J］.Ann Oncol,2014,25(7):1328-1333.
［20］LA Raedler.Akynzeo (Netupitant and Palonosetron),a dual-acting oral agent,approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting ［J］.American Health & Drug Benefits,2015,8:44-48.
［21］Dong Shuang,Yu Shiying.Study on the nausea and vomiting caused by different administration of cisplatin ［J］.Cancer Research,2013,40(09):890-893.［董爽,于世英.顺铂不同给药方案所致恶心呕吐的研究［J］.肿瘤防治研究,2013,40(19):890-893.］
［22］Jordan K，Kinitz I，Voigt W，et al.Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogeic multiple-day chemotherapy［J］.Eur J Cancer,2009,45(7):1184-1187.
［23］Albany C,Brames MJ,Fausel C,et al.Randomized,double-blind,placebo-controlled,phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5-HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens:a hoosier oncology group study［J］.J Clin Oncol,2012,30(32):3998-4003.
［24］Olver IN，Grimison P,Chatfied M，et al.Result of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy［J］.Support Care Cancer,2013,21(6):1561-1568.
［25］Chinese Cancer Rehabilitation and Palliative Treatment of Specialized Committee (CRPC),China ASCO Antitumor Drug safety Management Committee of Experts (ASMC).Guidelines for the prevention of tumor treatment vomiting (2014 Edition)［J］.J Clin Oncol,2014,3(19):263-273.［中国抗癌协会癌症康复与姑息治疗专业委员会(CRPC),中国临床肿瘤学会抗肿瘤药物安全管理专家委员会 (ASMC).肿瘤治疗相关呕吐防治指南(2014版)［J］.临床肿瘤学杂志，2014,3(19):263-273.］
［26］Jordan K,Sippel C,Schmoll HJ,et al.Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting:past,present,andfuture recommendations［J］.Oncologist,2007,12(9):1143-1150.
［27］Wu SJ,Xiong XZ,Lin YX,et al.Comparison of the efficacy of ondansetron and granisetron to prevent postoperative nausea and vomiting after laparoscopic cholecystectomy:a systematic review and meta-analusis ［J］.Surg Laparosc Endosc Percutan Tech,2013,23(1):79-87.
［28］Jordan K,Hinke A,Grothey A,et al.A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis［J］.Support Care Cancer,2007,15(9):1023-1033.
［29］Suzuki K,Yamanaka T,Hashimoto H,et al.Randomized,double-blind,phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy:TRIPLE study ［J］.Ann Oncol,2016,27(8):1601-1606.
［30］F Roila,B Ruggeri,E Ballatori,et al.Aprepitant versus metoclopramide,both combined with deamethasone,for the prevention of cisplatin induced delayed emesis:a randomized,double-blind study ［J］.Ann Oncol,2015,26(6):1248-1253.
［31］Navari RM.Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting［J］.Eur J Pharmacol,2014,722：180-186.
［32］Navari RM,Gray SE,Kerr AC.Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea：a randomized phase III trial［J］.J Support Oncol,2011,9(5):188-195.
［33］Mizukami N,Yamauchi M,Koike K,et al.Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy：a randomized，double-blind，placebo controlled study［J］.J Pain Symptom Manage,2014,47(3):542-550.
［34］Abe M,Hirashima Y.Efficacy and safety of olanzapine combined with aprepitant,palonosetron,and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer:KCOG-G1301 phase II trial［J］.Support Care Cancer,2016,24(2):675-682.